GPC3-targeting antibody-interferon alpha fusion protein and uses thereof
By developing the interferon alpha fusion protein of the target antibody of GPC3 with A and B chains, the poor efficacy of the existing GPC3 target antibody monoclonal antibodies and the stability and safety of the interferon alpha fusion protein were solved, and efficient killing of GPC3-positive tumor cells and safety against non-target cells were achieved, and the stability of the product was improved.
Patent Information
- Application Number
- JP2024533155
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-08-12
- Filing Date
- 2022-08-12
- Publication Date
- 2025-03-21
- Estimated Expiration
- 2042-08-12
AI Technical Summary
Existing monoclonal antibodies of target GPC3 (such as GC33) are not effective in treating diseases such as liver cancer, and there are problems with the stability and safety of interferon alpha fusion protein, resulting in insufficient toxic side effects and production stability.
A GPC3 target antibody interferon alpha fusion protein with A and B chains was developed. The amino acid sequences of the A and B chains were represented by SEQ ID NO: 1 and SEQ ID NO: 2, respectively. The fusion protein was produced by recombinant expression technology and improved its killing efficacy against target cells and its safety against non-target cells through specific structural design and ligation methods.
The GPC3 target antibody interferon alpha thaw protein significantly improves the killing efficacy of GPC3-positive tumor cells, reduces toxic side effects on non-target cells, and significantly improves the stability of frozen and freezing, reducing risks in production and transportation.